Breaking AI & Tech News Analyzed

A shock government‑backed report this week warned of the danger of a “lost generation” of young people in Britain, as the number of 16‑ to 24‑year‑olds not in education, employment or training (NEETs) rose to more than 1 million, roughly 13.5% of the cohort.Rising NEET Numbers Spark Alarm in the UKOfficial UK statistics show that 13.5% of young people are not in work or college, climbing to 15.8% among 18‑ to 24‑year‑olds – nearly one in six. The report, authored by former Labour cabinet minister Alan Milburn, warns that without decisive action the country could see a sustained “lost generation”.Comparative NEET Rates: UK vs NetherlandsUK NEET rate (16‑24): 13.5% overall, 15.8% for 18‑24 year olds.Netherlands NEET rate (15‑29, adjusted): 5.3% last year, consistently below 5% for over a decade.Potential impact: Matching the Dutch rate could move 600,000 more 18‑ to 24‑year‑olds into learning or earning.Why Dutch Vocational Pathways Keep Youth EngagedThe Dutch system centres on three pillars: strong vocational secondary education (MBO), a welfare safety net that prioritises engagement and rehabilitation, and financial incentives for employers. Around 70% of Dutch 16‑ to 19‑year‑olds in upper secondary education attend an MBO school, and 35% of under‑25s later study at technical or professional universities. By contrast, only 22% of UK 18‑ to 21‑year‑olds were on vocational courses in 2024.Technical education is treated as “the foundation of the economy”, with work‑based learning embedded in curricula – many students combine four days of school with one day of on‑the‑job training.Policy Levers Behind the Dutch Low NEET RateThe 2004 Work and Social Assistance Act devolved welfare programmes to municipalities, creating personalised, localised support that addresses mental health and long‑term illness. Local councils provide tailored engagement programmes, subsidised employment, and specialised training, preventing young people on incapacity benefits from falling through the cracks.Employers receive fiscal incentives, such as payroll‑tax cuts and direct subsidies that cover up to 70% of wages for chronically unemployed youth, as highlighted by the Youth Futures Foundation. Rotterdam’s city council, led by Tim Versnel, funds up to 70% of wages for young chronically unemployed people and offers holistic support covering mental resilience, substance‑use treatment, and financial literacy.What the UK Could Adopt to Reverse the TrendTo emulate the Dutch success, the UK might consider:Expanding vocational pathways and integrating work‑based learning into secondary education.Devolving youth‑welfare services to local authorities for more personalised support.Introducing targeted fiscal incentives for businesses hiring young workers, including wage subsidies and tax relief.Adopting a whole‑of‑life approach that combines education, mental‑health services, and financial literacy for chronically unemployed youth.While cultural and structural differences mean a direct copy is impossible, the Dutch experience offers a roadmap for reducing Britain’s NEET rate and revitalising its youth labour market.

The Discovery of PFAS in the Solent Strait Scientists have found high levels of toxic PFAS, or “forever chemicals”, in soil, water and throughout the marine food chain in the UK’s Solent strait, including at protected environmental sites, according to a new study. Extent of the Pollution In some samples, pollution was 13 times the safe threshold for coastal waters. Others, which were below legal limits for individual chemicals, failed tests for combined toxicity. The samples were taken from the Solent strait, which runs between the Isle of Wight and the mainland, forming part of the Channel. Sources of the Chemicals The chemicals are thought to have entered the environment from wastewater treatment plants, sewage outflows, historic landfills and nearby military sites. Researchers analysed government data, testing at water utilities, and their own samples from a dozen species of fish, seaweed and invertebrates. Impact on the Environment They found PFAS were entering the Solent in treated effluent from wastewater plants in Portsmouth and Fareham operated by Southern Water, the utility that provides drinking water and sewerage for Kent, Sussex, Hampshire and the Isle of Wight. The study also mapped 194 combined sewer overflow outfalls and more than 500 nearby historic landfills that researchers believe could also contribute to the pollution. Calls for Action Researchers said their findings highlighted the need to monitor chemicals in combination and to make a blanket ban on PFAS part of the government’s water reform agenda. Prof Alex Ford, a biologist at the University of Portsmouth and one of the study’s authors, said: “If there was an oil spill in the Solent that industry would have to pay for the restoration of those habitats, but that doesn’t happen with sewage.” Future Outlook The EU is moving towards a blanket PFAS ban, probably with some exceptions for medicine and other critical uses. The British government said it would consult on setting limits for the chemicals and carry out further tests when its own PFAS plan was published in February, promising a “framework … to understand where these chemicals are coming from, how they spread and how to reduce public and environmental exposure”.

The Global Initiative to Reproductive HealthIn a landmark development for women's healthcare, an unprecedented global collaborative effort has resulted in the official renaming of Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This significant shift in medical terminology aims to address long-standing concerns about the condition's name and bring fresh hope to the millions of women affected worldwide.The Evolution of PCOS TerminologyThe term 'Polycystic Ovarian Syndrome' has been used for decades to describe this common endocrine disorder affecting women of reproductive age. However, medical professionals and patient advocates have increasingly highlighted limitations in the current name, which focuses primarily on ovarian cysts while overlooking the broader metabolic and endocrine aspects of the condition.The new name, 'Polyendocrine Metabolic Ovarian Syndrome,' more accurately reflects the complex, systemic nature of the disorder, which involves multiple hormonal systems and metabolic processes beyond just ovarian characteristics.Understanding the Scope of PCOS ImpactPCOS/PMOS affects an estimated one in ten women of reproductive age globally, making it one of the most common endocrine disorders. The condition is associated with a range of symptoms including irregular menstrual cycles, hormonal imbalances, insulin resistance, and metabolic issues, which can significantly impact quality of life and long-term health outcomes.The renaming initiative represents a significant step forward in recognizing the complexity of this condition and improving both medical understanding and patient experiences.Shifting Medical Perceptions Through NamingThe terminology shift is expected to have profound implications for how healthcare providers approach diagnosis, treatment, and patient education. By emphasizing the metabolic and endocrine components of the condition, the new name encourages a more holistic approach to care that addresses the full spectrum of symptoms and health implications.For patients, the change represents validation of their experiences beyond reproductive concerns and recognition of the condition's systemic impact on overall health and wellbeing.The Future of Women's Metabolic HealthAs medical communities worldwide adopt the new terminology, researchers anticipate increased funding and focus on understanding the metabolic aspects of PMOS, potentially leading to more targeted treatments and improved outcomes for patients.This renaming effort underscores the importance of patient-centered approaches in medical terminology and sets a precedent for how conditions affecting women's health are described and understood in the future.

The Deadly School Fire At least eight students have been arrested on suspicion of arson after fire at a boarding school for girls in Kenya killed 16 students and injured 79, police said. The fire broke out in the early hours of Thursday at the Utumishi Girls Academy Senior School in Gilgil, west-central Kenya. Investigation and Arrests On Friday, the Directorate of Criminal Investigation said preliminary investigations had identified eight people as “persons of interest in connection with the planning and execution of the suspected arson attack”. “The eight girls have since been arrested and are currently in police custody,” the statement added. The Aftermath Student Hilda Njeri, who was in one of the dorms most-affected by the fire, told Al Jazeera she was still dealing with everything that happened. “I was badly injured on my leg, and my lower back was badly injured,” Njeri said outside the school on Friday, adding that the principal took the students to hospital and paid all bills for treatment. Government Response Kenyan Education Minister Julius Ogamba told reporters that early investigations found that two teachers had been informed of the students’ alleged plans, but failed to stop them. Ogamba added that the school failed to follow safety rules, citing overcrowding in the dorms and a locked emergency exit. The Kenyan government has disbanded the school board of management and will take appropriate legal and disciplinary action against any staff found to have neglected their duties, he said.

The USMCA Renegotiation The administration of United States President Donald Trump wants to increase the percentage of regionally produced content in North American-built vehicles to qualify for preferential treatment under the US-Mexico-Canada Agreement (USMCA) on trade to 82 percent, with 50 percent of that value produced in the US. Economic Implications The new proposal emerged amid negotiations to revise the USMCA in Mexico City, with Canada not present at the talks. The shift, if accepted, would be a major break from the current USMCA, which requires that 40 percent of the "core parts" value of North American passenger vehicles be produced in high-wage jurisdictions, effectively the US or Canada. The Data Analysis Canada's gross domestic product (GDP) declined, unexpectedly, at an annualised rate of 0.1 percent in the first quarter, Statistics Canada said on Friday, compared with a downwardly revised contraction of 1 percent in the fourth quarter of last year. The Impact Analysis The Canadian economy has been buffeted by, among other things, tariffs from Trump, who has threatened to annex the country and make it the 51st state of the US. Prime Minister Mark Carney was elected on the platform that he would strengthen and diversify the Canadian economy away from the US. The Prediction "Our forecast for growth to ramp up in H2 and through 2027 depends on a favourable USMCA renegotiation, an early end to the Middle East war, and resumption of normal commerce through the Strait of Hormuz," said Tony Stillo, director of Canada economics at Oxford Economics.

The LeadNew Jersey officials have declared a state of emergency and imposed a curfew in response to intensifying immigration protests that have swept across the state. The measures, announced late Thursday, mark a significant escalation in how authorities are addressing the growing demonstrations that have entered their second week.The Emergency DeclarationGovernor Phil Murphy signed the executive order establishing the curfew, which will run from 9 p.m. to 5 a.m. daily in affected municipalities. The declaration grants state police additional authority to maintain order and restrict assembly during nighttime hours. 'These extraordinary measures are necessary to protect both the protesters and the general public,' stated Murphy during a press conference.The protests, which began as demonstrations against recent federal immigration policies, have evolved into broader expressions of discontent over immigrant rights and treatment. Multiple cities across New Jersey have reported clashes between demonstrators and law enforcement, with property damage and arrests occurring in several locations.The Regional ResponseNew Jersey's action follows similar measures taken by neighboring states, including New York and Connecticut, which have also implemented heightened security protocols. The tri-state coordination represents a unified approach to managing what officials describe as 'unprecedented civil unrest' related to immigration issues.Immigrant advocacy groups have criticized the curfew as an infringement on constitutional rights. 'Peaceful assembly is a fundamental American right,' said Maria Rodriguez, spokesperson for the New Jersey Immigrant Coalition. 'This curfew disproportionately targets immigrant communities and will only escalate tensions rather than address the root causes of the protests.'The Economic ImpactThe ongoing demonstrations and subsequent curfew have begun to affect local economies, particularly in areas with high concentrations of immigrant-owned businesses. Several restaurants, retail shops, and service providers have reported reduced customer traffic and have adjusted their operating hours to comply with the curfew.Local chambers of commerce estimate that businesses in affected areas could lose millions of dollars in revenue during the duration of the emergency measures. Tourism officials are also concerned about potential long-term impacts on New Jersey's reputation as a welcoming destination.The Political FalloutThe curfew has quickly become a political flashpoint, with state legislators already planning hearings to examine the governor's emergency powers. Republican lawmakers have accused Murphy of overreach, while Democratic allies have expressed support for maintaining public safety.Nationally, the situation in New Jersey has drawn attention from both major parties, with immigration advocates and opponents alike using the events to advance their respective narratives. The Biden administration has issued a statement calling for 'calm and dialogue' while acknowledging the 'legitimate concerns' of protesters.The Path ForwardLegal experts anticipate that the curfew will face immediate legal challenges, with civil liberties organizations preparing to file injunctions. Constitutional law professor Jennifer Williams noted that 'while states have broad emergency powers, restrictions on assembly during nighttime hours have historically been subject to strict scrutiny by courts.'As the situation continues to develop, community leaders are calling for dialogue between protesters and officials to address the underlying issues driving the demonstrations. The coming days will likely determine whether the curfew successfully de-escalates tensions or further polarizes an already divided state.

World Health Organization Director-General Tedros Adhanom Ghebreyesu confirmed on 31 May 2026 that five individuals infected with the rare Bundibugyo Ebola strain have recovered, including four who will be discharged today and one who left the hospital on Friday. The announcement came as the WHO opened a new treatment centre in Bunia, Ituri province, DRC.First Recoveries Confirmed in Bundibugyo Ebola OutbreakThe recoveries represent the first documented successes against a strain that has no approved vaccine or specific therapy. Doctors Without Borders (MSF) had described the situation as “deeply alarming” due to rapid case growth and diagnostic challenges.Outbreak Statistics Highlight Ongoing ThreatSuspected cases: ~1,000Suspected deaths: >220Current confirmed cases in DRC: rising rapidly across Ituri provinceCross‑border impact: Uganda reports 1 death and 9 casesThe Bundibugyo strain historically carries a case‑fatality rate of up to 50%, intensifying concerns about containment.Health System Strain and Regional Risks IntensifyLimited testing capacity and the absence of approved medical countermeasures have stretched local health infrastructure. MSF warned that the response has not yet caught up with the epidemic’s speed, and the outbreak’s proximity to the Ugandan border raises the risk of cross‑border transmission.Outlook: Vaccine Development and Containment ProspectsWhile the recoveries provide a morale boost, experts stress that sustainable control will depend on accelerated vaccine research, expanded diagnostic capacity, and coordinated regional surveillance. The WHO’s new treatment centre aims to improve patient outcomes, but long‑term containment will require international funding and rapid deployment of experimental therapeutics.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."